How to Use Eloralintide
Complete guide to Eloralintide dosing, administration, timing, and protocol recommendations.
Quick Overview
Eloralintide (Eli Lilly code LY3841136) is an investigational, long-acting, selective amylin receptor agonist given as a once-weekly subcutaneous injection for obesity. Amylin is the satiety hormone your pancreas releases alongside insulin, and eloralintide is built to mimic it without the gut side effects that sink most appetite drugs. It is not approved anywhere yet, but it has cleared Phase 1 and a 263-person Phase 2 trial with weight loss up to roughly 20 percent, and Lilly has said it is moving into Phase 3.
Dosing Guidelines
Common Dose
120-240mg once daily (oral)
Frequency
Once daily
Dose Range
120-240mg per day
Note: Oral small-molecule GLP-1 agonist. No injection required. Phase 2 trial doses only. Longer half-life may support less frequent dosing in future formulations.
Administration Method
Oral tablet
Protocol Duration
36 weeks in Phase 2 trials
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (lower incidence than injectable GLP-1s)
- •Diarrhea
- •Vomiting
- •Constipation
- •Decreased appetite
Frequently Asked Questions
What is the recommended dose for Eloralintide?
120-240mg once daily (oral)
How do you administer Eloralintide?
Oral tablet
When is the best time to take Eloralintide?
Timing depends on goals. Research suggests optimal timing varies.
How long should you use Eloralintide?
36 weeks in Phase 2 trials
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.